Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dulaglutide vs Flaxseed: Dulaglutide has the stronger overall evidence (7 vs 6.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dulaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Dulaglutide and Flaxseed have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.
any
Subcutaneous once-weekly pen (Trulicity)
30g (about 3-4 tablespoons) of ground/milled flaxseed daily
with-meals
Ground / milled flaxseed
and 1 more not shown
Weeks to months
Months to years
Months
Especially during initiation/escalation
8-12 weeks
8-12 weeks
12 weeks
First 1-2 weeks
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet Diabetes Endocrinol (2019) · Meta analysis
Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet (2019) · Rct · n=9901
Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome
Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial.
Clin Nutr (2016) · Meta analysis · n=1302
15 trials (19 treatment arms), 1302 participants
Potent antihypertensive action of dietary flaxseed in hypertensive patients.
Hypertension (2013) · Rct · n=110
Double-blind, placebo-controlled RCT, 110 patients, 6 months
Flaxseed supplementation on glucose control and insulin sensitivity: a systematic review and meta-analysis of 25 randomized, placebo-controlled trials.
Nutr Rev (2018) · Meta analysis
25 RCTs (30 treatment arms)
Dulaglutide has a higher evidence score (7/10 vs 6.5/10) and wins in 2 of 3 categories.
For manage blood sugar, Dulaglutide has a higher relevance score (82 vs 42).
No known interactions between Dulaglutide and Flaxseed have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.